Navigation Links
Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
Date:6/19/2009

TROMS0, Norway and SEOUL, Korea, June 19 /PRNewswire/ -- The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cancer.

According to Lytix Biopharma CEO Gunnar Saelid and KAEL-GemVax CEO Jay Sangjae Kim, "We are delighted to announce this joint venture to test a combination of two very interesting experimental drugs. In preclinical models, LTX-315 has demonstrated the ability to effect necrotic killing of cancer cells. Simulatenously it also causes the release of warning signals from the stressed and dying cells that trigger activation of the immune system. On the other hand GV1001, a telomerase peptide vaccine in phase III trials, is one of the best documented anti-cancer vaccines currently in development, with a potentially broad utility against a range of cancer types.

"There is a strong scientific rationale for combining these agents, providing a local inflammatory response combined with specific vaccination - these two novel agents should have the potential to function as an efficient immunotherapy for the treatment of cancer," says Mr Jon Amund Eriksen, Director of Product Development, Oncology at Lytix Biopharma. Mr Eriksen is also one of the key persons, together with Professor Gustav Gaudernack, at the Norwegian Radium Hospital involved in the development of GV1001.

Speaking on behalf of their respective companies, business development spokespeople Anders Fugelli (Lytix Biopharma) and Michelle Kyunghee Kim (KAEL-GemVax) comment, "KAEL-GemVax and Lytix Biopharma will both contribute scientific and regulatory, as well as financial, support to the planned study in patients, sharing the results for use in the future clinical development programs for each proprietary agent. Lytix Biopharma will be responsible for
'/>"/>

SOURCE Lytix Biopharma AS
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lytix Closes USD 10.4 Million Funding Round
2. ZyGEM and Advalytix Partner to Produce Innovative DNA Extraction Products
3. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
4. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
5. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
6. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
7. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
8. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
9. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... Lawrence, MA (PRWEB) August 28, 2014 “This ... single test to screen from 0 to 150 ppb,” said ... test is a significant benefit to plant owners and USDA-GIPSA ... corn and other commodities. Testing can take place in a ... Not only can the plant test the feed and grain ...
(Date:8/28/2014)... BOSTON , Aug. 28, 2014  Next month, executives ... at three key industry events beginning with Patient-Centered Clinical ... Hotel in Boston , September 4-5. Patient ... , and Aaron Fleishman will share insights on ... how a variety of tactics – from media to mobile ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... Funding Milestone Continues Progress at Seneca, Illinois ... ... NBF ) announced today that it has satisfied the conditions ... million,senior secured credit facility with WestLB AG, one of the world,s ...
... Phase 2b Trial Expected to Begin in the ... 4 Mpex Pharmaceuticals, Inc. today,announced that the ... Products Development has granted Mpex orphan drug designation ... pulmonary,infections due to Pseudomonas aeruginosa and other bacteria ...
... the Chinese Pharmaceutical ... CHENGDU, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, ... and,supplier of modernized traditional Chinese medicine ("TCM") based ... members:,Professor Zunjian Zhang, Ph.D., Professor Jianping Hou, Ph.D. ...
Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 2Tianyin Pharmaceutical Appoints Three New Independent Board Members 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 4
(Date:8/28/2014)... A free mobile app called TX Invasives is now ... The University of Texas at Austin for identifying harmful ... , Invasive species in the United States cause about ... they destroy agricultural crops, clog waterways, kill native plants ... TX Invasives app for reporting where invasive species occur, ...
(Date:8/28/2014)... German . ... to a striking pattern of blue stripes alternating with golden ... cells, and yellow cells emerge during growth in the skin ... mosaic to compose the characteristic colour pattern. ,While ... interact to form proper stripes, the embryonic origin of the ...
(Date:8/28/2014)... 2014) Researchers at the University of Minnesota have ... (FSHD) to be used for muscle regeneration research as ... for FSHD. , The research is published in the ... , There is no treatment for FSHD, which is ... of muscular dystrophy. FSHD is an unusual genetic disorder ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3UMN researchers find animal model for understudied type of muscular dystrophy 2
... The tummy,s taste for red wine with red meat , ... happens when red wine meets red meat? If the rendezvous ... bounty of healthful chemical compounds may thwart formation of harmful ... study, which reinforces the benefits of consuming wine and other ...
... closer to understanding the recent demise of billions of honey ... a common bee virus. Deformed wing virus (DWV) is passed ... parasitic mite called Varroa destructor when it feeds. However, research ... General Virology suggests that the virus does not replicate ...
... of Crohn,s disease researchers has combined data from ... variants associated with the inflammatory bowel disorder, bringing ... Several of these are involved with the ... evidence that disruptions in a process called autophagy ...
Cached Biology News:American Chemical Society's Weekly PressPac -- June 25, 2008 2American Chemical Society's Weekly PressPac -- June 25, 2008 3American Chemical Society's Weekly PressPac -- June 25, 2008 4American Chemical Society's Weekly PressPac -- June 25, 2008 5American Chemical Society's Weekly PressPac -- June 25, 2008 6American Chemical Society's Weekly PressPac -- June 25, 2008 7American Chemical Society's Weekly PressPac -- June 25, 2008 8American Chemical Society's Weekly PressPac -- June 25, 2008 9Bee disease a mystery 2International team identifies 21 new genetic risk factors for Crohn's disease 2
...
Red Standard is sodium salt of resorufin....
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: